MARKET

FATE

FATE

Fate Therapeutic
NASDAQ
1.900
-0.010
-0.52%
After Hours: 1.870 -0.03 -1.58% 17:24 06/09 EDT
OPEN
1.950
PREV CLOSE
1.910
HIGH
2.090
LOW
1.820
VOLUME
1.89M
TURNOVER
--
52 WEEK HIGH
2.880
52 WEEK LOW
0.9100
MARKET CAP
221.46M
P/E (TTM)
-1.7433
1D
5D
1M
3M
1Y
5Y
1D
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 1d ago
Weekly Report: what happened at FATE last week (0601-0605)?
Weekly Report · 1d ago
Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR), Fate Therapeutics (FATE) and Edgewise Therapeutics (EWTX)
TipRanks · 4d ago
Fate Therapeutics Advances Off-the-Shelf CAR-T Autoimmune Pipeline
TipRanks · 5d ago
Gil Blum Reiterates Hold on Fate Therapeutics as Early FT819 Data Show Promise but Uncertain Durability
TipRanks · 5d ago
Fate Therapeutics Showcases Data Featuring Its CAR T-Cell Programs At European Congress Of Rheumatology
Benzinga · 5d ago
Fate Therapeutics reports Phase 1 data for FT819 CAR-T in lupus with reduced conditioning regimen
PUBT · 5d ago
Fate Therapeutics management to meet with Piper Sandler
TipRanks · 6d ago
More
About FATE
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing off-the-shelf, multiplexed-engineered, induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. The Company's pipeline includes iPSC-derived, chimeric antigen receptor (CAR)-targeted T-cell and NK cell product candidates. The iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. The Company's product candidates under development include FT819, FT522, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT825 is its first iPSC-derived CAR T-cell product candidate for the treatment of solid tumors being developed in collaboration with Ono Pharmaceutical. FT836 is the Company's multiplexed-engineered CAR T-cell product candidate targeting MHC proteins MICA and MICB.

Webull offers Fate Therapeutics Inc stock information, including NASDAQ: FATE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FATE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FATE stock methods without spending real money on the virtual paper trading platform.